In 2016 IPPOSI conducted a survey of 150 arthritis patients, and 21 Irish patient organisations, which found that:
- Patient awareness and understanding of biosimilars is very low, with the vast majority also unable to tell the difference between a biosimilar medicine and a generic medicine.
- That patients are more interested in the safety profile of a biologic or biosimilar medicine rather than its effectiveness.
- That patients have limited access to appropriate information on these treatments.
- That patient involvement and informed consent, is very important in any decision by medical practitioners to change patients from a current to an alternate treatment.
Full results are available in the outcome report. Downloadable results are available by clicking here.